Cargando…

P968: ALLOCATION AND VALIDATION OF THE SECOND REVISION OF THE INTERNATIONAL STAGING SYSTEM IN THE ICARIA-MM AND IKEMA STUDIES

Detalles Bibliográficos
Autores principales:	Perrot, Aurore, Richardson, Paul, Mikhael, Joseph, Martin, Thomas G., Beksac, Meral, Spicka, Ivan, Eduardo Capra, Marcelo, D’agostino, Mattia, Sonneveld, Pieter, Bisht, Kamlesh, Fukao, Taro, Zhang, Rick, Tada, Keisuke, Tekle, Christina, Macé, Sandrine, Klippel, Zandra, van de Velde, Helgi, Moreau, Philippe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431483/ http://dx.doi.org/10.1097/01.HS9.0000970776.33983.01

Ejemplares similares

P931: ISATUXIMAB IN RELAPSED MULTIPLE MYELOMA PATIENTS WITH ULTRA-HIGH-RISK CYTOGENETICS: ICARIA-MM AND IKEMA SUBGROUP ANALYSIS
por: Moreau, Philippe, et al.
Publicado: (2023)

Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA
por: Martin, Tom, et al.
Publicado: (2022)

P916: LONG-TERM OUTCOMES WITH ISATUXIMAB-CARFILZOMIB-DEXAMETHASONE (ISA-KD) IN RELAPSED MULTIPLE MYELOMA PATIENTS WITH 1Q21+ STATUS: UPDATED RESULTS FROM THE PHASE 3 IKEMA STUDY
por: Facon, Thierry, et al.
Publicado: (2023)

Subgroup analysis of ICARIA‐MM study in relapsed/refractory multiple myeloma patients with high‐risk cytogenetics
por: Harrison, Simon J., et al.
Publicado: (2021)

Revised international staging system allocation in the ICARIA‐MM study: Practical challenges and impact on outcome
por: Richardson, Paul G., et al.
Publicado: (2021)

Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study
por: Martin, Thomas, et al.
Publicado: (2023)

Correction: Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study
por: Martin, Thomas, et al.
Publicado: (2023)

Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high‐risk cytogenetics: IKEMA subgroup analysis
por: Spicka, Ivan, et al.
Publicado: (2022)

Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis
por: Schjesvold, Fredrik, et al.
Publicado: (2021)

Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis
por: Schjesvold, Fredrik, et al.
Publicado: (2022)

Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis
por: Dimopoulos, Meletios A., et al.
Publicado: (2020)

In response to: Treatment of patients with multiple myeloma progressing on frontline therapy with lenalidomide, Moreau et al., 2019
por: Klippel, Zandra, et al.
Publicado: (2019)

Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis
por: Facon, Thierry, et al.
Publicado: (2022)

Incidence of Diabetes in the Working Population in Spain: Results from the ICARIA Cohort
por: Vazquez, Luis Alberto, et al.
Publicado: (2018)

Evaluation of 968 children with corrosive substance ingestion
por: Karaman, İbrahim, et al.
Publicado: (2015)

Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis
por: Capra, Marcelo, et al.
Publicado: (2021)

Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis
por: Dimopoulos, Meletios A., et al.
Publicado: (2022)

The pattern of gynecological malignancies in 968 cases from Pakistan
por: Jamal, Shahid, et al.
Publicado: (2006)

Isatuximab plus carfilzomib and dexamethasone in Japanese patients with relapsed multiple myeloma: subgroup analysis of the randomized, open label, phase 3 IKEMA study
por: Ishida, Tadao, et al.
Publicado: (2022)

Correction to Lancet Planet Health 2022; 6: e968–76
Publicado: (2023)

Human Papillomavirus Prevalence and Type Distribution Among 968 Women in South Korea
por: So, Kyeong A, et al.
Publicado: (2016)

Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma
por: Bisht, Kamlesh, et al.
Publicado: (2023)

Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial
por: Dimopoulos, Meletios A., et al.
Publicado: (2020)

Additive effects of LPL, APOA5 and APOE variant combinations on triglyceride levels and hypertriglyceridemia: results of the ICARIA genetic sub-study
por: Ariza, María-José, et al.
Publicado: (2010)

Mechanistic studies of DepR in regulating FK228 biosynthesis in Chromobacterium violaceum no. 968
por: Qiao, Yongjian, et al.
Publicado: (2018)

Symptomatic venous thromboembolism and mortality in orthopaedic surgery – an observational study of 45 968 consecutive procedures
por: Lapidus, Lasse J, et al.
Publicado: (2013)

The Glutaminase-1 Inhibitor 968 Enhances Dihydroartemisinin-Mediated Antitumor Efficacy in Hepatocellular Carcinoma Cells
por: Wang, Diancheng, et al.
Publicado: (2016)

Editorial: “How to Improve Cord Blood Transplantation: By Enhancing Cell Counts or Engraftment?”
por: Beksac, Meral
Publicado: (2016)

Is There Any Reason to Prefer Cord Blood Instead of Adult Donors for Hematopoietic Stem Cell Transplants?
por: Beksac, Meral
Publicado: (2016)

EXTRAMEDULLARY DISEASE
por: Beksac, Meral
Publicado: (2022)

Antibody interference and response kinetics of isatuximab plus pomalidomide and dexamethasone in multiple myeloma
por: Hulin, Cyrille, et al.
Publicado: (2021)

Impact of ixazomib‐lenalidomide‐dexamethasone therapy on overall survival in multiple myeloma patients: Analysis of the emerging‐markets subgroup of the TOURMALINE‐MM1 trial
por: Spencer, Andrew, et al.
Publicado: (2022)

968 Changes in Serotypes of Group B Streptococcus in Infants with Invasive Bacterial Infection in Korea; from 1994 to 2013
por: Yoon, In Ae, et al.
Publicado: (2014)

DKK4 enhances resistance to chemotherapeutics 5-Fu and YN968D1 in colorectal cancer cells
por: He, Shengli, et al.
Publicado: (2017)

Experience of loneliness during the COVID-19 pandemic: a cross-sectional study of 50 968 adult Danes
por: Christoffersen, Lea AN, et al.
Publicado: (2023)

Prevalence and clinical characteristics of metabolically healthy obese individuals and other obese/non-obese metabolic phenotypes in a working population: results from the Icaria study
por: Goday, Albert, et al.
Publicado: (2016)

Role of Killer Immunoglobulin-Like Receptor and Ligand Matching in Donor Selection
por: Beksaç, Meral, et al.
Publicado: (2012)

How to Improve Cord Blood Engraftment?
por: Beksac, Meral, et al.
Publicado: (2016)

Natural Killer Cell-Mediated Cellular Therapy of Hematological Malignancies
por: Sahin, Ugur, et al.
Publicado: (2019)

Reformas en los Artículos 884, 885, 886 y 968 de la Ley federal del trabajo
por: Olivares Grajales, Viliulfo
Publicado: (1993)

Cannot write session to /tmp/vufind_sessions/sess_5sl58pfnr7huln027rbj1lkoqd